How Walgreens Turned Itself Around in Q3

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
How Walgreens Turned Itself Around in Q3

© patty_c / Getty Images

Walgreens Boots Alliance Inc. (NASDAQ: WBA) released its fiscal third-quarter financial results before the markets opened on Thursday. The company said that it had $1.47 in earnings per share (EPS) and $34.6 billion in revenue, which compared with consensus estimates of $1.43 in EPS and revenue of $34.46 billion. The same period of last year reportedly had EPS of $1.53 on $34.33 billion in revenue.

The Retail Pharmacy USA segment had third-quarter sales of $26.5 billion, an increase of 2.3% over the year-ago quarter. The Retail Pharmacy International segment had sales of $2.8 billion, a decrease of 7.3% from the year-ago quarter, reflecting an adverse currency impact of 5.7%.

The Pharmaceutical Wholesale segment had sales of $5.9 billion, a decrease of 1.7% from the year-ago quarter, due to an adverse currency impact of 10.0%. On a constant currency basis, sales increased by 8.3%, primarily reflecting growth in emerging markets.

Looking ahead to the fiscal 2019, the company maintained adjusted EPS guidance of roughly flat, at constant currency rates. Consensus estimates are calling for $5.99 in EPS and $136.88 billion in revenue for the full year.

[nativounit]

Stefano Pessina, executive vice chair and chief executive, commented:

Following a difficult second quarter, we made progress in the third quarter against the strategic goals we set, and are pleased to report an improvement in our U.S. comparable growth compared with the first half of the year. We will continue our aggressive response to rapidly shifting trends, and have already seen improved U.S. retail sales and prescription growth and are making good progress in implementing our Transformational Cost Management Program. Together, this gives us the confidence to reiterate the fiscal 2019 guidance we previously provided.

Shares of Walgreens traded up over 3% at $54.18 on Thursday, in a 52-week range of $49.31 to $86.31. The consensus price target is $57.90.

[recirclink id=556716]
[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618